WitrynaIn order to improve compliance on the posting of results, the primary aim of this communication is to remind all sponsors about their obligation for the reporting of clinical trial summaries in the EU Clinical Trials Database. In the spirit of the EU legislation, it is important that all stakeholders act Witryna12 kwi 2015 · The IMPROVE-IT trial, launched 9 years ago, has finally provided physicians with long-term efficacy and safety evidence for ezetimibe. The large-scale …
Digital adherence technologies to improve tuberculosis treatment ...
Witryna17 lis 2014 · A. Adding ezetimibe, a non-statin agent, to statin therapy reduces cardiovascular events in high-risk patients with acute coronary syndrome (ACS), according to results of the IMPROVE-IT Trial presented Nov. 17 at AHA 2014. The study was led by Christopher P. Cannon, MD, FACC, professor of medicine at Harvard … WitrynaFindings In a prespecified analysis of 15 281 patients enrolled in IMPROVE-IT, patients achieving an LDL-C level of less than 30 mg/dL at 1 month after acute coronary … norris jaclyn cosmetics
IMPROVE-IT TRIAL - CardiologyTrials.org
Witrynaplacebo‐controlled trial design, the benefit could have been due to the statin alone. SHARP What IMPROVE‐IT may add? Ezetimibe may modestly lower CV event risk … Witryna1 cze 2024 · PINNACLE Cohort and IMPROVE-IT Trial Patient Characteristics View LargeDownload 1. Cannon CP, Blazing MA, Giugliano RP, Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387-2397. PubMedGoogle ScholarCrossref 2. Maddox TM, Masoudi FA, Oetgen Witryna2 lis 2024 · IMPROVE-IT was a multinational, double-blind, randomised, placebo-controlled trial that enrolled 18 144 patients who had been stabilised after an acute coronary syndrome. Recruitment was from Oct 26, 2005, to July 8, 2010, and the trial reported its primary outcome in June, 2015. The trial was done in 1158 sites in 39 … how to remove yourself from viber group